Articles

Poll

Podcasts

Slideshows

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

In another interview segment, Cohen described several other major takeaways from his conference presentation on psoriasis, comorbidities, and therapies.

Jeffrey Cohen, MD: Mild Versus Severe Psoriasis, Recommended Therapies

In a conference interview, Cohen delved into the major takeaways covered in his presentation on the latest information related to psoriasis and its therapy.


Jeffrey Cohen, MD: Effects of Different Therapies on Psoriasis Comorbidities

New late-breaking data showed that oral roflumilast treatment was both safe and efficacious against psoriasis, making it a potentially less expensive and convenient treatment alternative.


Oral Roflumilast Effective, Safe in Treating Plaque Psoriasis Over 24 Weeks

New phase 2b data show the oral PDE4 inhibitor could reduce psoriasis area severity by more than 60% in 16 weeks.

Orismilast Tablets Significantly Clear Psoriasis Skin

New data indicates that an oral TYK2 inhibitor known as NDI-034858 showed strong results for psoriasis patients in a recent phase 2b trial.


Oral TYK2 Inhibitor Led to Significant Skin Clearance Improvement in Psoriasis

New data has indicated that patients with psoriasis who were not responding to ixekizumab or secukinumab responded well to risankizumab, an interleukin-23 inhibitor.


Risankizumab Led to Improvements for Psoriasis Patients Unresponsive to Secukinumab, Ixekizumab

Data presented in a research letter suggests that medicinal-thermal waters found in a spring in Las Salinas (near Madrid) had positive effects on plaque psoriasis.

Thermal Waters in Spain as Topical Treatment for Plaque Psoriasis

In another segment of his interview, Mark Lebwohl, MD, discussed the various ways to address different psoriasis patients depending on their backgrounds with obesity, cancer, and psoriatic arthritis.

Mark G. Lebwohl, MD: Psoriasis Drugs for Patients with Cancer, Obesity, Psoriatic Arthritis

In his recent interview, Mark Lebwohl, MD, spoke about his Winter Clinical Miami presentation titled ‘Psoriasis: Which Drug for Which Patient?’ and some of its highlights.

Mark G. Lebwohl, MD: Winter Clinical Presentation on Choosing the Right Psoriasis Drug

New research into the use of ustekinumab compared to other treatments for psoriasis sheds light on risk for outpatient infections.

No Risk of Outpatient Infections Identified for Pediatric Psoriasis Patients Starting Ustekinumab

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.